-Investor call with retinal expert Robert B. Bhisitkul , M.D., Ph.D., to be held on Tuesday, February 14, 2023 at 7:00 a.m. PT / 10:00 a.m. ET - -Complete 16- and 24-week safety and efficacy data from phase 2 ENVISION study in wet AMD expected in Q1 2023- SOUTH SAN FRANCISCO, Calif. , Feb.
SOUTH SAN FRANCISCO, Calif. , Jan. 18, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from January 3, 2023 , through January 17, 2023 , the Compensation
